Liquid-based cytology testing | BD Cervical cancer

Today’s challenges
- HPV primary screening requires reliable HPV tests
- Increasing laboratory pressure calls for integrated automation of HPV testing
- Reliable triage methods are key in HPV primary cervical cancer screening
- The importance of self-collection in HPV screening
- HPV primary screening requires reliable HPV tests
  The shift to HPV primary screening makes it essential to use reliable HPV tests that are clinically-validated for longer screening intervals and approved to use with self-collected samples in a vaccinated population.
  Increasing laboratory pressure calls for integrated automation of HPV testing
  Demographic shifts and a dwindling workforce are affecting laboratory organization. These labs are now exploring innovative strategies to alleviate staff pressure while still meeting the high demand for testing.
  Reliable triage methods are key in HPV primary cervical cancer screening
  By choosing a reliable triage test after an initial HPV primary positive result, clinicians can better identify women at high risk of cervical disease and reduce the need for unnecessary colposcopies and treatment for those women who are at lower risk.
  The importance of self-collection in HPV screening
  While providing similar performance as clinician-collected samples, self-collected samples have the potential to extend screening coverage and become a method of choice for the future of cervical cancer screening programmes.
BD Onclarity™ HPV Assay
- HPV extended genotyping to improve patient management
- BD Onclarity™ HPV Assay offers a reliable DNA-based PCR assay
- HPV Assay that gives flexibility in screening paradigm and sample type
- HPV Self-collection with BD Onclarity™ HPV Assay
- HPV testing automation adapted to your needs
- BD COR™ System: Comprehensive capabilities, breakthrough performance
- HPV extended genotyping to improve patient management
  The unique risk stratification design of the BD Onclarity™ HPV Assay with extended genotyping allows to focus on patients at most risk for more precise clinical decision-making.
  BD Onclarity™ HPV Assay offers a reliable DNA-based PCR assay
  The BD Onclarity™ HPV Assay is designed to reduce the number of false-positive and false-negative results so you can be confident in the results that you get.
  HPV Assay that gives flexibility in screening paradigm and sample type
  BD Onclarity™ HPV Assay is CE-marked, FDA-approved for primary screening and fulfills the Meijer criteria and is validated for use with multiple specimen types, including self-collected samples.
  HPV Self-collection with BD Onclarity™ HPV Assay
  The BD Onclarity™ HPV Assay provides a performant solution and convenient logistical chain to answer the growing demand for self-collection in HPV testing.
  HPV testing automation adapted to your needs
  With the BD Viper™ LT and the BD COR™ Systems, you can tailor your choice to the laboratory's capacity and needs of your laboratory, to enable greater throughput with the same staff.
  BD COR™ System: Comprehensive capabilities, breakthrough performance
  BD COR™ System enhances both laboratory outcomes and patient management with advanced molecular diagnostic capabilities.
BD SurePath™ Liquid-based Pap Test
- Accurate liquid-based cytology testing that enhances patient care
- Automate cervical cytology from sample to result
- Training for pathologists and cytotechnologists
- Accurate liquid-based cytology testing that enhances patient care
  The BD SurePath™ Liquid-based Pap Test offers higher cervical disease detection and a lower unsatisfactory rate compared to conventional cytology and other LBC devices.
  Automate cervical cytology from sample to result
  The BD SurePath™ Liquid-based Pap Test can be processed according to the throughput and automation levels needed, from sample to result.
  Training for pathologists and cytotechnologists
  BD offers a wide range of high-quality education programmes including online morphology training for pathologists and cytotechnicians.
BD Portfolio
- Fully integrated end-to-end cervical cancer screening solutions
- HPV testing solutions
- Cytology testing solutions for cervical cancer screening
- Fully integrated end-to-end cervical cancer screening solutions
  BD offers a complete portfolio of devices, assays, and instruments for every lab size and any screening method to keep you ahead of the curve in cervical cancer screening.
  HPV testing solutions
  Discover the BD Onclarity™ HPV Assay, our scalable portfolio of instruments for HPV testing automation, and our solutions for self-collection.
  Cytology testing solutions for cervical cancer screening
  Discover the BD SurePath™ Liquid-based Pap Test, our scalable portfolio to automate cytology from sample to result, and our education programmes.
Genotype evidence
- Extend the power of HPV testing
- FDA Clinical Trial
- Extended genotyping
- Assay design
- Persistence tracking
- Diagnostic challenges
- Extend the power of HPV testing
  FDA Clinical Trial
  Extended genotyping
  Assay design
  Persistence tracking
  Diagnostic challenges

Discover BD SurePath™ Liquid-based Pap Test

The BD SurePath™ Liquid-based Pap Test is an FDA and CE-marked cytology method with higher cervical disease detection and a lower unsatisfactory rate compared to conventional cytology and other liquid-based cytology (LBC) devices.¹

Reliable sample
collection

Standardised slide
preparation

Accurate results

Simple and efficient cell collection that ensures sample quality

Visual

The head of the collection device is deposited directly into the BD SurePath™ Collection Vial so 100% of the collected cells are sent to the laboratory for analysis – unlike the rinsing method which can result in up to 37% of cells being discarded.^2,3
The cells are preserved in an ethanol solution for optimal slide preparation in the lab.⁴
The same sample can be used for cytology testing, immunocytochemistry, and HPV testing.^4-6

See how BD SurePath™ can help you to collect cervical samples of high quality for cytology and molecular testing.

Video Player is loading.

Current Time 0:00

Duration 2:12

Loaded: 7.46%

Stream Type LIVE

Remaining Time 2:12

Unique and standardised sample processing that offers homogenous slides

BD SurePath™ Liquid-based Pap Test uses a proprietary cell enrichment process to eliminate blood, inflammatory cells, mucus and other debris. Only the most diagnostically relevant material is presented on the slide, offering a clear background.^7,8

Automated slide preparation with on-board staining results in a 13 mm deposition area and uniform distribution of the cells in a thin layer.⁹

Check out the quality of slides obtained with BD SurePath™ Liquid-based Pap Test

Accurate and definitive results that enhance patient care

Women* who are screened with BD SurePath™ Liquid-based Pap Test have a higher chance of having their precancerous lesions detected than women who are screened with either conventional cytology or other LBC devices.²

Compared to conventional cytology, BD SurePath™ Liquid-based Pap Test resulted in:¹
-58% in unsatisfactory reports
-29% in ASC-US/LSIL ratio
+64% in HSIL+ detection
+107% in LSIL+ detection

Decrease unsatisfactory reports

Increase the detection of cervical precancerous lesions

Decrease the risk of cervical cancer in the follow-up period

The BD SurePath™ Liquid-based Pap Test is your trusted partner from sample collection to result reporting.

BD solutions for
HPV testing

Today’s challenges BD Onclarity™ HPV Assay BD SurePath™ Liquid-based Pap Test BD Portfolio Genotype evidence

Shifting to HPV primary screening requires reliable HPV tests

HPV primary screening requires reliable HPV tests

Increasing laboratory pressure calls for versatile instrumentation

Increasing laboratory pressure calls for integrated automation of HPV testing

Reliable triage methods are key

Reliable triage methods are key in HPV primary cervical cancer screening

The importance of self-collection

The importance of self-collection in HPV screening

HPV extended genotyping to improve patient management

BD Onclarity™ HPV Assay offers a reliable DNA-based PCR assay

HPV Assay that gives flexibility in screening paradigm and sample type

HPV Self collection

HPV Self-collection with BD Onclarity™ HPV Assay

HPV testing automation adapted to your needs

BD COR™ System: Comprehensive capabilities, breakthrough performance

Automate cytology from sample to result

Automate cervical cytology from sample to result

Training for pathologists and cytotechnicians

Training for pathologists and cytotechnologists

Fully integrated end-to-end cervical cancer screening solutions

HPV testing solutions

Cytology testing solutions for cervical cancer screening

Extend the power of HPV testing

FDA Clinical Trial

FDA Clinical Trial

Extended genotyping

Assay design

Persistence tracking

Persistence tracking

Diagnostic challenges

ASC-US, atypical squamous cells of undetermined significance; FDA, Food and Drug Administration; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesions; LBC, liquid-based cytology; LSIL, low-grade squamous intraepithelial lesions; Pap, Papanicolaou; SIL, squamous intraepithelial lesions.

1. Fremont-Smith M et al. Cancer. 2004;102(5):269–79.
2. Nance KV. Diagn Cytopathol. 2007;35(3):148–53.
3. Bigras G et al. J Low Genit Tract Dis. 2003;7(3):168–74.
4. BD SurePath™ Collection Vial Package Insert (500017013).
5. CINtec® PLUS Cytology Kit Package Insert.
6. BD Onclarity™ HPV Assay Package Insert (8089899).
7. Sweeney BJ et al. Cancer Cytopathol. 2006; 108(1): 27–31
8. Kenyon S et al. Cancer Cytopathol. 2010;118(5):244–9.
9. BD Totalys™ SlidePrep Instrument User’s Manual (500005570).
10. Ransdell JS et al. Cancer Cytopathol. 1997;81(3):139–43.
11. Nygård JF et al. J Med Screen. 2004;11(2):70–6.
12. Rozemeijer K et al. BMJ. 2017;356:j504.